Nebenwirkungen · Ifirmasta (previously Irbesartan Krka)
Ifirmasta 75 mg film-coated tablets Ifirmasta 150 mg film-coated tablets Ifirmasta 300 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 8
HOS-209843 · Präparat HOS-154383
Investigations: Very common: Hyperkalaemia* occurred more often in diabetic patients treated with irbesartan than with placebo. In diabetic hypertensive patients with microalbuminuria and normal renal function, hyperkalaemia (≥ 5.5 mEq/L) occurred in 29.4% of the patients in the irbesartan 300 mg group and 22% of the patients in the placebo group. In diabetic hypertensive patients with chronic renal insufficiency and overt proteinuria, hyperkalaemia (≥ 5.5 mEq/L) occurred in 46.3% of the patients in the irbesartan group and 26.3% of the patients in the placebo group.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-06T17:53:00Z · SHA-256 e433703ffd9bd808c0192a313a2ee367aa7dd908ac40549e8c4904a5f65b0d76 · Passage f8d02954d22cddff149ac76edfadfd45484ee62a995ddff54bc826596a946597 · Zeichen 3211–3880 im Abschnitt